HERTFORDSHIRE, England and PITTSBURGH, Aug. 9, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results for the quarter and six months ended June 30, 2017.
Second Quarter 2017 Financial Highlights
Total revenues of $2.96 billion, up 16% compared to the prior year period
North America segment third party net sales of $1.28 billion, down 9%; and up approximately 4% excluding the decrease in sales of the EpiPen® Auto-Injector of approximately $172 million
Second Quarter 2017 Financial Highlights
Total revenues of $2.96 billion, up 16% compared to the prior year period
North America segment third party net sales of $1.28 billion, down 9%; and up approximately 4% excluding the decrease in sales of the EpiPen® Auto-Injector of approximately $172 million
